|
Thomas Verhoeven Ph.D. was named to the newly created position of vice president for process and product development in June 2003. At the same time Verhoeven became a member of the Lilly Research Laboratories policy committee. In August 2003 he became a member of the senior management council.
Verhoeven joins Lilly from Merck where he most recently served as senior vice president of global operations and strategic research planning for Merck Research Laboratories. At Lilly Verhoeven will oversee the technical management and commercial development aspects of Lilly's worldwide operations of process and product development for both biological and pharmaceutical drug candidates.
Verhoeven received a bachelor of science degree in chemistry from the University of Michigan and a doctorate in organic chemistry from the University of Wisconsin. He was a National Institute of Health (NIH) fellow at Stanford University and is a recipient of the NIH's post-doctoral fellow award. Verhoeven is a member of the American Chemical Society. He holds a total of 46 patents across a range of technologies including the synthetic application of poly-anion intermediates asymmetric hydrogenation enantioselective reduction and bioconversions.
Prior to joining Lilly Verhoeven worked for Merck Research Laboratories for 23 years. Within Merck Research Laboratories he held responsibility for the process development and commercialization of multiple products across a range of therapeutic classes. Most recently as Merk's senior vice president for global operations and strategic research planning Verhoeven was responsible for developing and managing the strategic and annual operating plans for the research division. Verhoeven's research interests have spanned multiple disciplines including the use of poly-anion intermediates in synthesis enantioselective reduction methods bioconversion applications and catalyst activation. He has published and lectured widely in these fields. | 